^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    LYN mutation

    i
    Other names: LYN, LYN Proto-Oncogene Src Family Tyrosine Kinase, V-Yes-1 Yamaguchi Sarcoma Viral Related Oncogene Homolog, Lck/Yes-Related Novel Protein Tyrosine Kinase, Tyrosine-Protein Kinase Lyn, P53Lyn, P56Lyn, JTK8
    Entrez ID:
    4067
    Related biomarkers:
    Expression
    Fusion
    Others
    5ms
    Establishment of the Bcwm.2 Cell Line As a BTK-Inhibitor Resistant, BCL2 Inhibitor Sensitive in Vitro and In Vivo Study Model for Waldenström's Macroglobulinemia (ASH 2023)
    2 cells did not respond to the BTK-inhibitors ibrutinib, zanubrutinib or pirtobrutinib but were sensitive to the BCL2 inhibitor venetoclax. BCWM. 2 represents a novel, BTK-inhibitor resistant, BCL2 inhibitor sensitive WM cell line that demonstrates MYD88 (S243N) and LYN (I297N) somatic activating mutations, and deletions of 6q. BCWM.
    Preclinical • IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • LYN (LYN Proto-Oncogene Src Family Tyrosine Kinase) • IRF4 (Interferon regulatory factor 4) • SPI1 (Spi-1 Proto-Oncogene) • HDAC5 (Histone Deacetylase 5) • RUNX3 (RUNX Family Transcription Factor 3)
    |
    MYD88 mutation • LYN mutation • IRF4 expression
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • Brukinsa (zanubrutinib) • Jaypirca (pirtobrutinib)
    over1year
    Dynamic change of soluble interleukin-2 receptor distinguished molecular heterogeneity and microenvironment alterations in diffuse large B-cell lymphoma. (PubMed, Biomark Res)
    There was a positive correlation between transcripts of IL-2R and immune checkpoint expressions including PD-1 and CTLA-4. Our findings identified that dynamic change of sIL-2R, with this simple and easy detection method in peripheral blood, had long-term prognostic effect and specific relation to microenvironment alterations in DLBCL.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    RET (Ret Proto-Oncogene) • ARID1A (AT-rich interaction domain 1A) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • KMT2D (Lysine Methyltransferase 2D) • IL2RA (Interleukin 2 receptor, alpha) • CD4 (CD4 Molecule) • IL2 (Interleukin 2) • LYN (LYN Proto-Oncogene Src Family Tyrosine Kinase) • SOCS1 (Suppressor Of Cytokine Signaling 1)
    |
    ARID1A mutation • RET mutation • MYD88 mutation • KMT2D mutation • CTLA4 expression • LYN mutation • SOCS1 mutation